Daily Market Updates: A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Global Markets

Home›Global Markets›North America›A little-known biotech’s high-stakes cancer bet just p…

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Reported · Written up by our desk · North America

Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.

← Newer storyMultistrategy hedge funds face rising risks from leverage and crowded…Older story →BHEL share price target: Already up 50% in 1 year, should you still b…

More like this

Global MarketsCorn futures hit four-month low on big US crop, export worries

Global MarketsFake bomb threats on flights and cruise ship cause travel disruption in Europe

Global MarketsSullivan: What the 2026 midterms could mean for energy investors

Global MarketsSugar Slides to Five-Week Low as High Indian Output Jolts Market

Global MarketsMeta seeks to raise up to $25 billion in debt sale as AI spending jumps

Sources

CNBC WorldA little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Global Markets

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

More like this

Sources

Get the close, explained.